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EVALUATION OF UPPER MOTOR NEURON PATHOLOGY IN AMYOTROPHIC
LATERAL SCLEROSIS BY MRI: TOWARDS IDENTIFYING NONINVASIVE
BIOMARKERS OF THE DISEASE

VENKATESWARAN RAJAGOPALAN

ABSTRACT
Amyotrophic lateral sclerosis (ALS) is the commonest adult motor neuron disease
(MND) which causes progressive muscle paralysis and death usually within 5 years of
symptom onset. As a result, only ~30,000 individuals in the United States are afflicted at
any one time even though 5,000 or more individuals are diagnosed yearly. The diagnosis
of ALS requires evidence of degeneration in upper motor neurons (UMNs) in the brain
and in lower motor neurons (LMNs) that exit the brainstem and spinal cord to innervate
skeletal muscles. Diagnosis can be incorrect or delayed when disease is early or atypical
because non-invasive objective tests of UMN involvement do not exist, unlike
electromyography to assess the LMN. Although magnetic resonance imaging (MRI) of
brain and spinal cord is used primarily to identify conditions which mimic ALS, novel
MRI sequences and post-processing techniques can identify macroscopic and even submacroscopic changes in ALS brain related to neuronoaxonal degeneration (e.g., in
corticospinal motor tracts). MRI-based techniques like diffusion tensor imaging (DTI)
and proton magnetic resonance spectroscopy (1H-MRS), as well as nuclear medicine
modalities like positron emission tomography (PET) and single photon emission
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tomography (SPECT) are being used to study brains of patients with ALS. Many previous
MRI studies of ALS brain are limited either in methodology or information obtained
being primarily qualitative, i.e. changes visible to the naked eye (macroscopic). This
study employed both routine and novel MRI sequences to objectively assess gray and
white matter pathology of the brain in ALS patients, including T2 relaxometry, DTI, and
voxel based morphometry (VBM) of 3D high resolution T1-weighted images. DTI
metrics showed significant (p<0.05) changes in rostral extent of corticospinal tract (CST)
in ALS patients with predominantly UMN symptoms and signs, and the ALS-dementia
patients, whereas more caudal involvement was observed in ALS patients with classic
findings of UMN and LMN dysfunction. Significant (p<0.05) grey matter volume and
cortical thickness reductions were observed only in the ALS dementia group when
compared to controls, which suggests that neurodegeneration might begin as a
neuronopathy in these patients. Preserved grey matter volume and cortical thickness in
other ALS patients suggests a dying back axonopathy and warrants further study. To our
knowledge this is the first study in a large number of ALS patients categorized into
different subgroups based on their clinical presentation. Future comparisons of brain MRI
and post-mortem histopathology in the same patient will allow radiopathologic
correlation of tissue pathology underlying the radiographic changes, including CST
hyperintensity. These may reveal differences in pathogenic mechanisms causing ALS
which could respond differently to novel pharmacotherapies.
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CHAPTER I
INTRODUCTION TO AMYOTROPHIC LATERAL
SCLEROSIS

1.1 Amyotrophic Lateral Sclerosis (ALS)
According to the National Institute of Neurological Disorders and Stroke (at the
NIH) at least 30,000 Americans1 are afflicted with ALS and approximately 5,000 new
cases are diagnosed annually. The term ALS is derived from ‘amyotrophic’ refering to
muscle atrophy or weakness which signifies disease of the lower motor neuron (LMN)
and ‘lateral sclerosis’ refering to scarring or gliosis of the lateral columns of the spinal
cord, which indicates degeneration of the corticospinal tract portion of the upper motor
neuron (UMN) 2. ALS is the commonest adult motor neuron disease (MND) that causes
progressive degeneration of UMNs, which arise in the cerebral cortex
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and of LMNs,

which arise in the brainstem and spinal cord. This results in weakness, atrophy and
spasticity of skeletal muscles involved in limb movement, speech, swallowing, and
breathing. The disease is sporadic in ~90% of cases and familial in ~10% 2, 3. ALS affects
individuals of all races in all geographic areas equally except for some minor exceptions
like in Western Pacific where the prevalence is 50 times higher than elsewhere

1

2, 3

. The

peak age of onset is between 50 and 70 years, with increasing age being the most
important risk factor for developing ALS. In addition, patients developing ALS younger
than 41 years tend to survive longer than those with onset older than 60 years 3. Males are
affected 1.5 to 2.0 times more often than females, although this reaches unity (1:1) over
65 years of age 3. Average survival after the onset of ALS symptoms is ~3 years with
mean disease duration reported to be between 31 and 43 months3. The cause of ALS and
its site of origin within the nervous system are unknown and it is universally fatal.

1.2 Diagnosis
ALS is relatively easy to diagnose when advanced or its fully developed classic
form with combined UMN and LMN dysfunction, although there are exceptions to this 4.
Diagnosis of ALS may be difficult and even be missed a) when atypical features occur, b)
during certain stages of the disease when UMN or LMN features predominate, c) because
a number of diseases can mimic ALS, including multiple sclerosis, radiculomyelopathy,
multifocal motor neuropathy with conduction block, myasthenia gravis, and myopathy3,
and d) because no single test definitively diagnoses ALS, and diseases that mimic it need
to be excluded.

All this results in diagnostic errors with some reporting only approximately 60%
of ALS patients to be diagnosed correctly on their initial evaluation3. At present,
diagnosis is based on consistent clinical features, evidence of disease progression, and
laboratory investigations (e.g., blood tests, electromyography, and neuroimaging)
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excluding conditions which resemble or mimic ALS, as mentioned above 5. As a result,
the delay between symptom onset and definitive diagnosis of ALS averages 12 months.
Considering 80% of patients survive only 3-5 years from onset of symptoms 2, shortening
the time to diagnosis is imperative. There is great interest in identifying biomarkers of
ALS which could allow earlier diagnosis, identification of disease subtypes (which exist
phenotypically) and monitoring of disease progression to assess efficacy of
pharmacotherapies.

Based on the World Federation of Neurology El Escorial criteria 6, ALS is
diagnosed only when there is evidence of both UMN and LMN dysfunction in the
absence of other mimicking pathologies. This may be complicated in earlier stages or
atypical forms of disease when UMN or LMN changes predominate rather than both
motor neuron pools showing clinical dysfunction. Electromyography (EMG) provides an
objective measure of LMN involvement even when it is not obvious clinically, but no
equivalent exists for assessment of UMN dysfunction

7, 8

. On the other hand, prominent

LMN changes like muscle atrophy, hypotonia, and hyporeflexia can mask coexistent
UMN signs arising from degeneration of cortical motor neurons and their projections.
Novel applications of neuroimaging as a noninvasive objective measure of UMN
involvement could assist in such diagnosis as well as provide insights into disease
pathogenesis and progression.

Presently, neuroimaging of brain and spinal cord of patients evaluated for ALS is
used primarily to exclude pathologies that can mimic disease, such as strokes, tumors,
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inflammation, demyelination, and compression 3. Conventional magnetic resonance
imaging (cMRI) is the commonest imaging modality used for these purposes now.
Special MRI applications like diffusion tensor imaging (DTI), proton magnetic resonance
spectroscopy (1H-MRS), and nuclear medicine techniques like positron emission
tomography (PET) and single photon emission tomography (SPECT) are increasingly
being used to identify changes potentially specific to ALS 3, 9.

1.3 Neuroanatomy
For technical reasons, the UMNs in the brain are most accessible to MRI
techniques that may reveal changes specific to ALS. A general understanding of the
neuronal regions and tracts commonly affected in ALS is necessary to analyze and
interpret the MRI changes.

Cortical UMNs which project to lower brainstem spinal cord LMNs are localized
primarily in layer V of the precentral gyrus (Broca’s area 4). The axons of all
corticomotoneurons descend through the subcortical white matter through the corona
radiata and centrum semiovale in a somatotopic orientation before entering the internal
capsule and brainstem. Motor axons arising from cortical neurons in the far lateral
hemisphere that travel within the corticobulbar tract, pass through the genu of the internal
capsule to finally terminate on motor nuclei in dorsal regions of the midbrain, pons or
medulla. In contrast, axons arising from more parasagittally located corticomotoneurons
and traveling in the corticospinal tract (CST) pass through the posterior limb of the
internal capsule to enter the brainstem. These CST fibers subsequently pass sequentially
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through the cerebral peduncle of the midbrain, basis pontis, and finally pyramidal tract of
the medulla prior to decussating at the cervicomedullary junction of the upper cervical
spinal cord 3. Pictorial representations of corticobulbar and corticospinal tracts are shown
in Figures 1 and 2. Both of these central motor axon tracts degenerate in ALS to varying
degrees depending on the distribution of disease.

Pons
Medulla

Figure 1: Pictorial diagram of Corticobulbar tract.
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Motor cortex

Pyramidal decussation

Lateral CST

Figure 2: Pictorial diagram of corticospinal tract.
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Typical clinical features when UMNs of the corticobulbar pathway degenerate
include slurring of speech (dysarthria), swallowing difficulty (dysphagia), facial
weakness, and spasticity (increased jaw jerk, facial reflexes, hyperactive gag), as well as
pseudobulbar affect (pathologic laughter and crying). When corticospinal pathway
UMNs are affected, typical clinical features include limb spasticity causing loss of finger
dexterity and gait instability, limb and trunk weakness, and pathologically increased
stretch reflexes 3.

1.4 Neuroimaging in ALS
Among the different neuroimaging modalities available today, MRI is preferred
because it is noninvasive and can provide different contrasts between tissues types
depending on the sequences used. This allows detection of abnormalities in ALS that are
not detected by other modalities such as computed tomography (CT) 3. Continued
improvements in MRI hardware (e.g. higher field strength magnets) and development of
novel sequences and post-processing techniques have resulted not only in life-like images
but also means to quantify abnormalities of structure and function. Examples of novel
MRI techniques being used to identify structural and even functional brain pathology in
ALS include diffusion tensor imaging (DTI)10 and functional MRI (fMRI)11 developed in
the 1990’s.

7

1.5 Project Aim
The etiology of ALS and its site of origin within the central nervous system (CNS)
are unknown. By definition, the diagnosis of ALS is based on identifying motor neuron
degeneration in both the CNS and peripheral nervous system (PNS), which can also be
termed the upper motor neuron (UMN) and lower motor neuron (LMN), respectively.
However, whether ALS neurodegeneration begins in the CNS or PNS is debated. In
reference to a CNS (or UMN) origin, where degeneration begins is also unknown.
Theoretically, it can begin anywhere along the rostrocaudal extent of the motor neuron
pathway: in the motor neuron cell body (perikaryon) located in the cerebral cortex gray
matter, as a neuronopathy, or along the motor axon in the subcortical white matter, as an
axonopathy as shown in figure 3 below. If ALS is a neuronopathy, degeneration will
proceed in an anterograde (proximal to distal or rostral to caudal) fashion with axon
pathways affected later; if it is an axonopathy, degeneration will be retrograde (distal to
proximal or caudal to rostral) with the perikaryon affected later. Based on preliminary
data, the author hypothesizes that classic and UMN–predominant ALS is predominantly a
dying back axonopathy with retrograde degeneration of the perikaryon. This is in contrast
to patients with ALS and frontotemporal dementia (FTD) in whom the author
hypothesizes neurodegeneration to begin in the neocortex (as a neuronopathy) with
anterograde degeneration of the UMN. By testing these hypotheses, this study aims to
identify biomarkers of the disease process which may help in making early diagnoses and
provide insights into pathogenic mechanisms.

8

Cell body or
soma

Myelin

Axon
Origin if
neuronopathy
Dendrites

Origin if
axonapathy

Figure 3: Schematic of neuronopathy and axonopathy locations in a neuron

Even though ALS patients have clinical evidence of both UMN and LMN
dysfunction, a large percentage of patients begin with UMN abnormalities and
subsequently develop LMN signs. It is observed that some patients with predominantly
UMN signs have bilateral CST hyperintensities visible on routine T2, proton density, and
FLAIR images, while others do not, even though both groups have comparable degrees
of clinical UMN dysfunction and duration of disease. The explanation for this difference
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in the presence or absence of CST hyperintensities is unknown. It is hypothesized that in
UMN-predominant ALS patients without CST hyperintensities, the UMN degeneration is:
(1) below the threshold of detection by routine MRI but still predominantly axonal, (2)
arising in the cerebral cortex (as a neuronopathy) or (3) arising extracranially in the spinal
cord (as an axonopathy).
The above paragraphs suggests that pathological mechanisms of ALS may be
different in ALS patients with predominant UMN signs with and without CST
hyperintensity and those of classic ALS and ALS with dementia. For instance clinical
signs indicate more caudal onset of neurodegeneration (e.g. spinal cord) in classic ALS
patients when compared with UMN predominant or in ALS dementia patients. In order
to gain better insight into the pathophysiological mechanisms of ALS disease process it is
imperative to categorize ALS patients. Therefore in this study ALS patients were
categorized based on their clinical symptoms and clinical evaluation of their conventional
MR images; 1) ALS patients with predominant UMN signs when compared to LMN
signs (based on their clinical evaluation) and in addition showed hyperintense signal
along CST (based on their conventional T2 and PD weighted images), 2) ALS patients
with predominant UMN signs when compared to LMN signs (based on their clinical
evaluation) without any hyperintense signal along the CST (based on their conventional
T2 and PD weighted images), 3) ALS patients with classic features i.e. no predominance
in either UMN and LMN signs (based on their clinical evaluation) and 4) ALS patients
with dementia (based on their clinical evaluation, conventional MR images and PET
scan).
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As shown in figure 4 below, T2 relaxometry and diffusion tensor imaging (DTI)
will be used to interrogate axonal integrity within the corticospinal tract (CST), the major
descending white matter motor tract and T1 imaging to examine volume (using voxel
based morphometry, VBM) and thickness of the cerebral cortex as measures of neuronal
integrity. These results will be compared to ALS patients with typical combined UMN
and LMN signs, ALS patients with FTD, and neurologic control patients without ALS or
UMN deficits.

T2 Relaxometry
Axonal Integrity (white matter
especially corticospinal tract)
Diffusion Tensor Imaging (DTI)

Voxel Based Morphometry (VBM)
Neuronal Integrity (grey
matter)
Cortical Thickness

Figure 4: MR imaging techniques to investigate axonal and neuronal
integrity in ALS
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Chapter II discusses quantitative T2 relaxometry technique employed in
investigating axonal integrity within CST in UMN predominant ALS patients with and
without CST hyperintensity.

In Chapter III a novel non invasive modality called diffusion tensor imaging
based on anisotropic diffusion property of water molecule in various neuronal fiber tracts
was employed to investigate axonal integrity of CST in ALS patients. The main
advantage of this technique over other conventional quantitative techniques is its ability
to discern different neuronal fiber tracts within WM structures which otherwise appear
homogeneous (conventional T1 or T2 weighted images).

Diffusion tensor metrics was

used to determine whether the presence or absence of CST hyperintensities in UMNpredominant ALS patients results from (1) divergent pathologies in subcortical axons (if both
groups show similar changes) or (2) degeneration of the perikaryon in motor cortex or
extracranial CST (if differences are found between groups). These results were then
compared to ALS patients with typical combined UMN and LMN signs, ALS patients with
FTD, and neurologic control patients without ALS.

Chapter IV discusses assessment of neuronal integrity in ALS patients using high
resolution T1 weighted images. Quantitative measurements techniques such as voxel based
morphometry and cortical thickness were employed to assess grey matter volume changes in
ALS dementia patients for evidence of cortical atrophy. These results were then compared
with ALS patients with typical (combined UMN and LMN signs), ALS patients with
predominant UMN signs and neurologic control patients without ALS.
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CHAPTER II
T2 RELAXOMETRY IN ALS

2.1 Introduction

Routine MRI studies using T2 weighted (T2-w), proton-density, and fluid
attenuated inversion recovery (FLAIR) weighted images occasionally identify
hyperintense signal along the CST 1 in a ALS patient as shown in Figure 5.

Figure 5: Routine MR imaging, T2-weighted axial (left) and sagittal (right)
MR brain images show corticospinal tract hyperintensity (arrows) in a UMNpredominant ALS patient
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Previous studies1 have demonstrated this change in 17% to 67% (median 40%) of
ALS patients although a preliminary analysis at the Cleveland Clinic found this change in
~31% of ALS patients. Based on one radiologic-pathologic study, such hyperintensity
represents demyelination and wallerian degeneration of the descending CST fibers2. Such
CST hyperintensity occurs in some but not all patients with very prominent UMN
findings3 .

Most previous MRI studies of ALS brain have described qualitative changes i.e.
relying on visual evaluation of disease related abnormalities4. Such qualitative evaluation
depends greatly on several factors, including: quality of the MR image (e.g. signal to
noise ratio, SNR), limits of visual detectability, the interpreter’s experience and image
reproducibility. These limitations can be minimized if the MR images can be
quantitatively assessed. Some such quantitative MR image sequences which are currently
employed in diagnosis of neurological diseases are magnetization transfer ratio (MTR),
T2 relaxometry, DTI and T1-w volumetric imaging. The first study will focus on T2
relaxometry as quantitative measures of ALS brain pathology.

The premise of T2 relaxometry is the quantitative comparison of T2 relaxation
times obtained from tissues which have different densities either normally (e.g., gray
matter vs white matter) or because of pathology (e.g. motor fibers either healthy or
undergoing wallerian degeneration). The basis of proton-based MR imaging is, in
sequential order, the alignment of body protons (1H) in a static magnetic field (B0), the
perturbation of this alignment by the application of a radiofrequency (RF) pulse

16

perpendicular to the direction of B0, the excitation of protons whose frequencies are in
resonance with the RF field, and the return to steady state (equilibrium) of the protons by
emission of this acquired energy. Body protons transfer this energy in two ways: (1) spin
lattice relaxation when energy is emitted to their neighboring lattice due to mechanical
motion and vibration; (2) spin-spin interaction when energy is transferred between
closely adjacent protons. This latter process is known as T2 relaxation. In solids, where
protons are more tightly packed and spin-spin relaxation is increased, T2 time will be
short. In contrast, in liquids where protons are farther apart and spin-spin relaxation is
decreased, T2 time will be long5 . Differences in T2 relaxation times may reflect
structural changes arising from disease; for example, edema results in a prolonged T2
relaxation time as more fluid accumulates.

Previous studies6, 7 of T2 relaxometry in ALS used dual echo sequences because
of clinical scanning time constraints and protocol simplicity. However, dual echo
sequences are limited by inadequate sampling of the T2 decay curve8 , dependency on
echo sampling intervals9, 10, poor signal to noise ratio8, 11 . Many T2 relaxometry studies12,
13

have employed fast spin echo (FSE) dual-echo sequence to measure T2 relaxation

times. However, FSE sequence is prone to high spatial frequency effects. High spatial
frequency effects occurs due to contrast averaging i.e. only the echo corresponding to
effective TEs forms the center of the k-space, and the remaining echoes in the turbo
factor or echo train length occupy other slabs of the k-space, resulting in a T2 contrast
that will have some dependence on spatial frequency13. The concern here was that the use
of data from a dual echo FSE sequence to measure T2 via the typical monoexponential fit
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method would not accurately measure T2 relaxation time in all brain regions i.e. the
signal in regions of high spatial frequency will correspond to a temporal evolution
different than the “effective” echo time used in the fit. Thus, some error will occur
depending on the spatial frequency characteristics of the brain region of interest. On the
other hand, for a SE sequence, all signal is measured at approximately the same time and
there will be no spatial frequency-dependence. The multiple-echo SE sequence will more
properly measure T2 relaxation time in all regions regardless of spatial characteristics.

2.2 Aim
The aim of this study is to evaluate the accuracy of T2 relaxation times along the CST
and whole brain white and grey matter structures derived from dual-echo FSE sequences
relative to multiple-echo SE sequences. If the error values along CST are found to be
within acceptable limits (< 10%) then T2 relaxation values measured using the dual-echo
FSE sequence will be used to evaluate pathophysiology of ALS.

2.3 Hypothesis
It is hypothesized that errors of T2 relaxation times based on dual echo FSE sequence
would be large in high spatial frequency regions (i.e. at brain structure edges), but small
in low spatial frequency regions such as the CST.
If the above hypothesis is true, then T2 values from dual echo FSE sequence will be
used to investigate the following hypotheses. It is hypothesized that in UMNpredominant ALS patients without CST hyperintensities, UMN degeneration is either: (1)
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below the threshold of detection by routine MRI but still predominantly axonal, (2)
arising in the cerebral cortex (as a neuronopathy) or (3) arising extracranially in the spinal
cord (as an axonopathy).

2.4 Methods
2.4.1

Image sequences

Clinically obtained MRI data and storage of de-identified images was approved by
our local Institutional Review Board as part of the “Neuroimaging Registry/Database for
CNS Analysis in Patients with Motor Neuron Disease”. Both dual-echo FSE and
multiple-echo SE images were acquired axially in 9 subjects (8 ALS patients and 1
control) aged 49 to 84 (63±11.7, mean±SD) years on a 1.5 T MRI scanner (Siemens
Symphony, Erlangen, Germany). Dual-echo FSE imaging parameters were: number of
slices = 40, contiguous, slice thickness = 4 mm, in-plane resolution = 0.9×0.9 mm; pulse
sequence parameters were: TR = 3900 ms, TE = 26 ms and 104 ms, echo train length or
turbo factor = 7, and number of averages = 1; total scan time = 3.5 minutes. Multipleecho spin echo imaging parameters were: number of echoes =16, number of slices = 8,
covering the upper half of the brain, slice thickness = 4 mm, slice gap = 4 mm, in-plane
resolution = 1.3×0.9 mm; pulse sequence parameters were: TR = 3900 ms, 16 TEs
ranging from 22-352 ms, number of averages = 1; total scan time = 7.5 minutes. A high
resolution 3D T1-w MPRAGE sequence provided good grey-white matter contrast
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.

MPRAGE imaging parameters were: number of slices = 160, contiguous, slice thickness
= 1 mm, in-plane resolution = 0.9×0.9 mm; pulse sequence parameters were: TR = 1970
ms, TE = 4.38 ms, number of averages = 1, flip angle =10o, TI =1100 ms and scan time =
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6.45 minutes. DTI was also performed using EPI sequence along 12 diffusion weighted
(b = 1000 s/mm2) directions and one b0 = 0 s/mm2 for identification of CST. Imaging
parameters were: 30 slices, 4 mm thick, with 1.9×1.9 mm in-plane resolution; pulse
sequence parameters were: TR = 6000 ms, TE = 121 ms, EPI factor = 128, number of
averages = 6 and scan time = 7.54 minutes. Because EPI-based DTI data is geometrically
distorted by susceptibility artifact at bone-air-tissue interfaces, gradient-echo sequence
field map images were acquired. Field map imaging parameters were: number of slices =
30, slice thickness = 4 mm, slice gap = 4 mm, TR=500 msec, TEs = 6.11 and 10.87 msec.

2.4.2

Data processing

Relaxation of signal intensity after a spin echo pulse sequence is given by equation
15.
Signal (S)
……..…………………………….1
Where M0 is proton density, T1 and T2 are longitudinal and transverse relaxation
times.TR timing was set long enough in the imaging protocol to exclude T1 effects14 . T2
relaxation times are then estimated by assuming a mono exponential decay model which
is as given in equations 2 below.
………………………………………………… 2
S0 being a parameter of no interest, the images are then log transformed and the final
equation which is used to calculate T2 map is given in equation 3 below.
..………………………………………………. 3
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TE2 and TE1 are the echo timings, and S1 and S2 are the image signal intensities at the two
echo time points, respectively.
Using the above equation, T2 relaxation times are calculated for every voxel resulting in
a T2 map. Since only mono-exponential fit is possible with the FSE sequence the SE data
were fitted with the same mono-exponential model. All SE images were linearized by log
transformation and a linear least square fit was used to estimate the T2 decay curve using
all sixteen echos. A percentage error map was then calculated from the T2 maps obtained
from SE and FSE sequences, as given in equation 4 below.

……………..…..…….4

2.4.3 Regional T2 relaxation values
Two approaches were taken to validate T2 relaxation times derived from FSE
sequences compared to SE sequences. The first was to assess error values of T2
relaxation times along the CST in ALS patients. DTI was used to generate tractography
maps identifying exact location of each patient’s CST. The second was to assess T2
relaxation time error across whole brain GM and WM structures.
2.4.3.1 CST T2 relaxation time error values
T2 relaxation time error values were calculated along the CST in the following
manner: (a) CSTs are reconstructed from the patient’s own DTI images after correction
of field distortion by using FUGUE from FSL (http://www.fmrib.ox.ac.uk/fsl/)15, 16. (b)
Undistorted

DTI

images

are

processed

using

DTI

Studio

open

software

(https://www.mristudio.org/)17) to estimate diffusion tensor matrix for each element in the
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voxel is calculated based on multivariate linear least square fit, and the obtained tensor
matrix is diagonalized to derive eigenvalues and eigenvectors. (c) Virtual neuronal fibers
are reconstructed using the fiber assignment by continuous tracking (FACT) algorithm 17,
which is described in detail elsewhere18. The tracking parameters used were: termination
FA threshold value = 0.2 21 and bending angle threshold = 41o.

After these preliminary processing steps, CST fiber tracts were reconstructed after
Wakana et al19 by placing one region of interest (ROI) caudally in the cerebral peduncle
and another rostrally just below the primary motor cortex. Subsequently, a map of CST
tracts was obtained and DTI images were registered to T2-w images by co-registering
b=0 images with T2-w images using an affine transformation (FLIRT from FSL)20.
Finally, the transformation matrix was applied to the CST tracts and a CST mask image
was created in order to superimpose them over the calculated error maps as shown in
figure. 6. Compared to manually tracing the ROI, we found that this tractography-based
method gives more accurate identification of the CST, is highly reproducible as it is free
of operator bias, and is less time intensive. T2 relaxation error values (percentage error as
given in equation 4) were obtained along the intracranial CST, percentage error values
were plotted as histograms for left and right CST separately as shown in figures 7) and 8)
and the mode values of the peak of the histograms were measured as error value in each
and every subject and are given in Table I
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CST Right

CST Left

Coronal slice view

Axial slice view
CST Left

CST Right

Figure 6: CST tracts superimposed on T2 relaxation map in one of our ALS
patients
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Figure 7: Histogram of absolute percentage error values along left CST in
one of our subjects

Figure 8: Histogram of absolute percentage error values along right CST in
one of our subjects
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2.4.3.2 Whole brain T2 relaxation time error values
All

image

processing

was

done

with

FSL

open

software

(http://www.fmrib.ox.ac.uk/fsl/)16. GM and WM segmentation was performed on T1-w
MPRAGE images because they provide good grey-white contrast. T2 relaxation time
error maps were calculated from whole brain WM and GM structures in the following
manner: (a) Brain and non-brain structures were extracted using BET21, and the extracted
brain image was segmented into WM, GM and CSF probability maps using FAST22 . (b)
Affine registration was used to register T1-w images to T2-w images using FLIRT20, 23 .
(c) The transformation matrix was then applied to WM and GM maps. (d) A binary mask
of WM and GM was created by setting a threshold value of P> 0.75 to eliminate any
misclassified WM, GM or CSF tissues. (e) WM and GM masks were then multiplied with
the percentage error map to obtain whole brain GM and WM error values as shown in
figure 9 a) and b). Processing steps from a) to d) was pictorially represented in figure 10
below. Error values of T2 relaxation times in GM and WM structures were then plotted as
histograms. Figure 11 a) and b) shows typical histogram of WM and GM error values in
one of our subjects .Mode values of the peak of the histograms were measured as error
value in each and every subject and are given in Table II..
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Error in %

Error in %
a.)

b)
.

Figure 9: MR images of Grey matter a)and White matter b) absolute
percentage error maps in one of our subjects
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PD

T1-W
image

T2-W

Brain
Extraction

Segmentation

T2 map

WM probability map

GM probability map

GMT2map

WMT2map

Figure 10: Pictorial representation of processing steps for whole brain
approach
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a)

b)

Figure 11: Histogram of whole brain absolute percentage error values of a)
white matter b) grey matter structures in one of our subjects
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2.5 Results
T2 relaxation value errors calculated from FSE vs. SE sequences in all 9 brains
are shown for the CST (Table I), and for whole brain WM and GM structures (Table II).
In the CST, error values were >10% in all subjects and >20% in 6 of 9 subjects (Table I).
This was surprising since we had initially hypothesized that T2 relaxation value errors in
the CST would not be high (>10%) since this region should normally not have high
spatial frequency characteristics. Large errors would be expected only in brain regions
with high spatial frequency because FSE sequences have pronounced high spatial
frequency effects. On the other hand, whole brain GM and WM regions generally had
low error values (<10%), although 6 subjects had error values slightly >10% in WM
regions (Table II). Overall, WM and GM T2 relaxation values were similar between FSE
and SE derived sequences suggesting a greater proportion of low vs. high spatial
frequency regions in whole brain. Also unexpected was the lowest percent error occurring
in the GM fraction considering the cortical surface would be expected to exert high
spatial frequency effects.
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Table I: Mode values of absolute percentage error in T2 Relaxation Times
along Right and Left Corticospinal Tracts measured from histogram in all
the subjects

Mode values of

Subject

absolute percentage error
Left CST

Right CST

1

15.56

19.67

2

18.16

19.14

3

26.53

18.55

4

21.55

22.53

5

22.58

18.51

6

23.5

24.63

7

23.64

9.58

8

18.84

23.76

9

30.63

20.02

Mean

22.33

19.59

SD

4.55

4.39

SD- Standard deviation
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Table II: Mode values of absolute percentage error in T2 Relaxation
Times in whole brain gray and white matter structures measured from
histogram in all the subjects
Subject

% Error
WM

GM

1

12.5

4.5

2

15.5

2.5

3

12.5

1.5

4

16.5

3.5

5

2.5

3.5

6

8.5

1.5

7

8.5

47.5

8

13.5

2.5

9

16.5

38.5

Mean

11.83

11.72

SD

4.60

17.90

SD- Standard deviation

2.6 Discussion
T2 relaxometry studies in ALS by Hofmann et al.6, and Tanabe et al.,7 used a
dual-echo SE sequence to measure relaxation times along the CST of patients and control
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subjects but failed to detect significant differences between groups. Reasons for this may
include small sample size 7, manual ROI identification of the CST region 6, 7 and different
MR sequence parameters such as TEs 30 ms and 100 ms 6 vs. 20 ms and 80 ms 7. Another
reason may be the inherent error caused by dual-echo sequences in measuring T2
relaxation time, as demonstrated in an earlier single slice study by Whittall et al.10 They
found that T2 values were underestimated with a dual-echo sequence using a
monoexponential fit

when compared

to

a 32-echo

CPMG sequence using

multiexponential fit, which produced more accurate relaxation times10. Even though 32echo single slice studies are considered to be the gold standard for accuracy of T2
relaxation times, limiting measurements to a single slice because of time constraints may
miss important information as ALS pathology may be located in other regions.

Duncan et al

9

showed that dual-echo FSE sequences are less accurate when

compared to dual-echo SE sequences. The large error in T2 relaxation values derived
from FSE sequences along the CST brings into question the validity of results in studies
using this technique. This is even more important when longitudinal measures are
performed because the significance of changes detected over time may not be valid.
Especially in diseases like ALS, it is imperative to have a robust measure of T2 relaxation
times where longitudinal studies are vital not only to study effects of disease progression
but also to assess the effects of potential disease modifying agents.

Undoubtedly, the main drawback to obtaining multiple-echo SE sequences is the
increased scanning time; in our study, acquiring 16 echoes over 8 slices (with 4 mm slice
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gap) took 8 minutes whereas acquiring 40 contiguous slices with a FSE sequence took
only 3.5 minutes. In clinical scanning protocols, this is a major consideration since other
sequences are also acquired, such as MPRAGE images and DTI, as in our study. The
patient’s ability to remain motionless in the scanner is also limited, especially when
dementia or other co-morbidities exist. This may be the reason why many T2 relaxometry
studies of patients with Huntington’s disease

13

, epilepsy

12, 24

, and multiple sclerosis25

have used FSE sequences. The increasing use of ultra-high field strength magnets (e.g.,
3T and higher) and the development of novel scanning sequences will likely overcome
the time limitations of multi-echo sequences.

Finally, the Carr-Purcell-Meiboom-Gill (CPMG) sequence is generally accepted
as a more accurate way to measure T2 with MRI. Future work should include the use of
the CPMG sequence to understand issues related to in vivo T2 measurements for clinical
studies.

2.7 Conclusion
The results clearly demonstrates that T2 relaxation times obtained using dual-echo
FSE sequences are not as accurate as values estimated from data acquired using multipleecho SE sequences. Therefore, T2 relaxometry based on dual-echo FSE sequence will not
be used further to investigate the changes in ALS patients. Based on above findings it is
recommended that future T2 relaxometry studies employ multi-echo SE sequences or
CPMG for accurate and reliable results.
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2.8 Limitations and Future Scope
The percentage error estimation method adopted in this study may raise concerns
about the level of acceptable error i.e. ~10%. To overcome the above the drawback
student t-test map can be obtained in order to determine significant difference between
the T2 relaxation maps of dual echo FSE and multiple echo SE sequences.
Low percentage error values seen in whole brain grey matter structures suggest
that T2 relaxation time measured using dual echo FSE sequence can be used to
investigate changes in grey matter structures. Future studies can be directed along this
line.

In the next chapter our second study using novel non invasive modality called
diffusion tensor imaging (based on anisotropic diffusion property of water molecule in
various neuronal fiber tracts) was employed to investigate axonal integrity of CST in
ALS patients. The main advantage of this technique over other conventional quantitative
techniques is its ability to discern different neuronal fiber tracts within WM structures
which otherwise appear homogeneous in conventional MR images (e.g. T1 or T2
weighted images). Diffusion tensor metrics was used to evaluate pathophysiological
changes in ALS patients when compared to controls.
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CHAPTER III
DIFFUSION TENSOR IMAGING IN ALS
3.1 Introduction
Onset of a disease is accompanied by pathologic changes initially at the
microscopic level, before becoming evident macroscopically. Detecting such changes as
early as possible is best for purposes of diagnosis and treatment of any disease process.
Unlike other conventional MR techniques, diffusion tensor imaging (DTI) is based on
diffusion of water molecules at the microscopic level. DTI’s efficacy and power in
providing this microscopic information non-invasively enabled clinicians and researchers
to study ALS along the line of multiple sclerosis1, 2 and other motor neuron disease
(MNDs)3, 4. As mentioned in section 1.5 of chapter 1, DTI is an appropriate tool to study
axonopathy in MNDs.

DTI is a relatively recently described modality based on the freedom with which
water molecules (protons) move randomly within tissue5 . Because DTI is based on this
microscopic level event, it is unique among MR modalities and has the potential of
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detecting tissue pathology at near sub-macroscopic levels. Identifying tissue pathology by
MRI before it has progressed significantly has several advantages, including more timely
diagnosis and earlier therapeutic intervention. In a progressive neurodegenerative disease
like ALS, DTI may non-invasively detect pathologic changes which are still at or near
microscopic levels. In addition, because most nerve fiber tracts are compact bundles of
myelinated motor axons oriented in parallel (e.g., CST or ascending tracts), their DTI
characteristics will be different whether healthy (intact) or undergoing degeneration
(disrupted).

Highly coherent structures like axon bundles do not allow protons (of water
molecules) to diffuse freely in all directions, isotropically. Rather, they restrict protons to
move primarily in one direction (along their length), anisotropically; densely packed fiber
bundles therefore normally possess high anisotropy and their disruption results in
decreased anisotropy. By measuring the magnitude of proton diffusion in multiple
directions, fiber (and tract) orientation can be determined6.

However, in order to

determine directionality of highly convoluted or irregular fiber tracts without scanning in
an excessive number of directions, a tensor model based on a limited number of diffusion
direction measurements was developed6. This is the origin of the term diffusion tensor
imaging (DTI) and figure 12 below shows how diffusion information is encoded in the
tensor matrix.
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Figure 12: Representation of water diffusion becoming anisotropic in the
presence of compact tissues and how that information is encoded in diffusion
tensor matrix.

The diffusion tensor matrix obtained from diffusion data contains both scalar and
vectorial measures. Scalar diffusion measures, i.e., fractional anisotropy (FA) and mean
diffusivity (MD), are widely employed because they are vector invariant (independent of
the direction of measurement) and provide quantitative information7. The most widely
evaluated scalar parameters in ALS are MD and FA given in equations 1 and 2 below. FA
represents the amount of anisotropy in the diffusion tensor 8 which is increased by fiber
tract coherence and integrity and reduced by demyelination or degeneration. MD
represents proton diffusion within one or more voxels (region)8 which decreases as water
molecules are more restricted in movement.

…………………………………………………….(1)
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..............................................................................(2)

Conventional MRI and DTI produce significantly different images, as shown in
figure 13 below. In conventional T1-w MRI, white and gray matter is visually
distinguishable because of contrast differences but white matter myelin appears mostly
homogeneous (Fig. 13a). In DTI, the directionality of fiber orientation in white matter
produces contrast differences and provides additional tract information (Fig. 13b) 6 . An
elegant extension of DTI is tractography, in which fiber tracts can be reconstructed in
three dimensions based on vector information from the tensor matrix (Fig. 13c).
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a)

b)

c)

Figure 13: Brain MRI of one of our ALS subjects showing: a) T1 weighted
image, b) DTI FA color map based on vector information (i) red color for left-right
orientation, (ii) green for antero-posterior direction and (iii) blue for rostrocaudal
orientation; and c)CST neuronal tracts reconstructed based on DTI tractography

As can be seen from the previous paragraphs that DTI images are not only more
informative when compared to conventional MRI scans but also have the ability to detect
microscopic changes occurring at very early stages of the disease process. This will
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enable the detection of pathologic changes at a much earlier stage and potentially before
the disease advances to an irreversible state. Furthermore, the tractography feature of DTI
will enable not only reconstruction of virtual neuronal fiber tracts which are affected by
the disease process but also identification of newer fiber tracts which might be prone to
ALS degeneration.

Previous DTI studies in ALS employed two different approaches in assessing fiber
tract integrity: ROI-based and voxel-based morphometry (VBM). The ROI-based
approach is hypothesis directed and is best suited when there is a priori knowledge about
regions that are affected by the disease process. On the other hand, the VBM based
approach assumes no prior knowledge about the regions affected by the disease process
and is therefore an exploratory one.

3.1.1

ROI-based approach

Many DTI studies in ALS have used ROI based identification of the CST at various
levels to compare FA and MD values between patients and control subjects. Most of these
studies revealed reduced FA and increased MD in the posterior limb of the internal
capsule in ALS patients compared to controls7-10. Hong et al11 used trace information
(which is the sum of diagonal elements of the eigen values of the DTI matrix) to
overcome errors introduced by partial volume effects when manually tracing CST in the
medullary pyramids. On the other hand, Schimrigk et al10 used a probability mixture
model which would overcome some but not all drawbacks of the ROI based approach.
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The advantage of this model is that it is independent of the resolution of the data and by
dividing the voxels within the ROI into a) pure fibers class, b) pure background class and
c) a partial volume class of both fiber and background class reduces not only partial
volume effects but also interobserver differences. Nonetheless, ROI based approaches
which require manual identification of brain regions which are labor intensive, are prone
to poor inter- and intrarater reproducibility, and generate partial volume effects.

3.1.2

VBM-based approach

Voxel-based morphometry (VBM) analysis allows objective and automated
detection of structural differences in brain tissue (e.g. atrophy) between subjects after
normalizing for random shape differences12. Being an unbiased assessment, it can be used
for exploratory analyses when no a priori knowledge of distribution in pathology is
available. For example, atrophy in ALS may occur outside of motor regions, especially
when patients have additional dementia, making VBM-based morphometry an ideal
approach to studying this. Once the patient’s brain is fitted to a common brain template
(e.g., from normal controls) which normalizes for any random variation between brains
shapes and sizes, it is smoothed and a statistical parametric map generated of grey and
white matter from which significant differences in tissue amounts is identified between
patient and control brain templates.

A VBM-based approach has been applied to DTI measures. Sach et al13 and
Thivard et al14 generated statistical parametric maps of FA values and found reductions
not only in CST and pyramidal tracts but also in the thalamus, corpus callosum and in
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other extramotor regions of ALS brains when compared to controls. In contrast, Abe et
al15 found changes only in the CST and pyramidal tracts. The disparate results may be
due to different patient phenotypes with varying degrees of involvement in non-motor
brain regions supporting the notion that ALS is a multisystem disease16.

Since our DTI data has large slice thickness contributing significantly to partial
volume effects and anisotropic voxels leading to poor signal to noise ratio (SNR), VBM
based approach will not be followed in this study.

3.1.3

Fiber Tractography

Virtual fiber tracts can be generated in 3D from quantitative DTI information (fiber
tractography) providing a visual correlate to the data. Abe et al15

first employed

tractography in ALS to accurately localize the supratentorial CST. In their more extensive
study, Wang et al17 used color maps and fiber tracking in ALS to show a thinning of the
CST in ALS compared to control brain. They also showed a reduction in CST fiber
number in ALS patients compared to control individuals. Although mean CST volumes in
right and left hemispheres were not different between affected and unaffected
hemispheres, the total CST volume in both hemispheres was significantly lower in ALS
patients compared to healthy volunteers.

Fiber tractography is sensitive to angular threshold, vector step length, and seed ROI;
it also shows variability among subjects because of anatomical differences.
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3.2 Limitations of current ALS DTI studies

Some of the limitations of the above mentioned studies are: a) manual ROI
identification, b) Changes in FA values can result from either decrease in axial diffusivity
or increase in radial diffusivity or could be due to both18. It is also demonstrated using an
example that even if a patient and a control subject have same FA values their individual
axial and radial diffusivities may vary greatly18. FA (equation 2) being calculated taking
into account all the eigen values cannot show differences when one or more eigen values
increase or decrease. In other words, FA can differentiate neither radial ( λ⊥ =

λ 2 + λ3
2

)&

axial ( λll = λ1 ) diffusivity figure 14, nor the tubular ( λ1 > λ2 ≈ λ3) & planar anisotropy
( λ1 ≈ λ2 > λ3) as shown in figure 15 below.

λ1
λ2
λ3

Figure 14: Axial and radial anisotropies Lambda 1 (λ1) being along the fiber
called as axial anisotropy and λ2 & λ3 being perpendicular to fiber orientation so
their average named as radial anisotropy
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A)

B)

Figure 15: Ilustration of Tubular anisotropy ( λ1 > λ2 ≈ λ3 ) A)and planar
anisotropy ( λ1 ≈ λ2 > λ3) B). (where green and blue colors indicate different fiber
populations)

So in order to overcome the above drawbacks we propose to study radial and axial
diffusivities, and Westin’s CP = (λ2- λ3)/λ1 and CL = (λ1- λ2)/λ1 for tubular and planar
anisotropy 19, 20. As can be seen from the above definitions CL will be bright for tubular
regions and dark for planar regions and CP on the other hand will be bright for planar
regions and dark for tubular regions.

Other important issues that will be addressed in this work are: a) categorizing
ALS patients into various subgroups and b) evaluating susceptibility artifacts in CST.
Many DTI studies in ALS failed to categorize/classify ALS patients appropriately based
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on their clinical symptoms thereby leading to inconclusive results7, 17. Since ALS patients
manifest themselves with variable clinical symptoms (like predominant UMN, classic
ALS, or predominant LMN symptoms) it is imperative to categorize them according to
their clinical symptoms rather than pooling them under a single category of “ALS”.
Motivation to categorize ALS patients came from the observance of hyperintense signal
along CST in T2-weighted images in some but not all of the ALS patients with
predominant UMN signs21, 22. It is intriguing to know whether there is any difference in
DTI metrics between UMN predominant ALS patients with and without hyperintensity
along CST. We believe that categorization will enable us to better understand the
pathophysiological mechanisms of ALS, for instance DTI measures will be used to
determine whether the presence or absence of CST hyperintensities in UMN-predominant
ALS patients results from (1) divergent pathologies in subcortical axons (if both groups
show similar changes) or (2) degeneration of the perikaryon in motor cortex or
extracranial CST (if differences are found between groups). Therefore, ALS patients were
categorized into four different groups namely; a) predominant UMN ALS with
hyperintense signal along CST (observed in their T2-weighted images), b) predominant
UMN ALS without CST hyperintensity, c) ALS patients with mixed UMN and LMN
signs (classic ALS), and d) ALS patients with frontotemporal dementia (FTD).

Most of the DTI studies in ALS employed single shot echo planar imaging (SS-EPI)
sequence7, 9, 10, 13, 15, 23-25. SS-EPI suffers greatly from susceptibility artifacts at air-tissuebone interfaces. Since most of the clinical DTI protocols are inherently devoid of field
map acquisition scan we aimed to investigate the effects of susceptibility artifacts along
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CST.

3.3 Aim
The goal of this study is to evaluate pathology in ALS using scalar DTI metrics like
fractional anisotropy (FA) along the CST. We also aimed to explore the usefulness of
indices namely; radial and axial anisotropy, Westin’s CP and CL, which are yet to be
studied in ALS.

3.4 Hypothesis
It is hypothesized that a) DTI metrics (FA, RA, MD, radial and axial diffusivities)
will be significantly different in the CST among ALS subgroups and between ALS and
control groups. b) If there is no difference in DTI metrics between CST hyperintense and
non-hyperintense groups then there are divergent pathologies in subcortical axons. c) In
classic ALS with mixed UMN and LMN findings, disease onset is more caudal when
compared to UMN predominant ALS patients. d) CST will not be significantly affected
by susceptibility artifacts.

3.5 Method
3.5.1

DTI Protocol

Clinically obtained MRI data and storage of de-identified images was approved by
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the Institutional Review Board at the Cleveland Clinic as part of the “Neuroimaging
Registry/Database for CNS Analysis in Patients with Motor Neuron Disease”. DTI data
of 8 control subjects (5 men, 3 women), 13 UMN predominant with CST hyperintensity
ALS patients (C-group) (8 men, 5 women), 21 UMN predominant without CST
hyperintensity ALS patients (B-group) (15 men, 6 women), 12 ALS patients with
predominant LMN signs

(E-group) (9 men, 3 women) and 14 ALS patients with

dementia (D-group) (3 men, 11 women) was obtained using 1.5 T system (Siemens
Symphony, Erlangen, Germany). DTI was performed using echo planar imaging (EPI)
sequence along 12 diffusion weighted (b = 1000 s/mm2) directions and one b0 = 0 s/mm2.
Imaging parameters were: 30 slices, 4 mm thick, with 1.9×1.9 mm in-plane resolution;
pulse sequence parameters were: TR = 6000 ms, TE = 121 ms, EPI factor = 128, number
of averages = 6 and scan time = 7.54 minutes. Gradient-echo field map images were
acquired to correct for geometrical distortion caused by susceptibility artifacts. Field map
imaging parameters were: number of slices = 30, slice thickness = 4 mm, slice gap = 4
mm, TR=500 msec, TEs = 6.11 and 10.87 msec.

3.5.2

Data processing

DTI images were first corrected for distortion effects using FSL’s FUGUE
(http://www.fmrib.ox.ac.uk/fsl/)26-28. Undistorted DTI images were then processed using
DTI Studio open software (https://www.mristudio.org/)29.. DTI matrix for each voxel was
calculated based on multivariate linear least square fit. The tensor matrix was then
diagonalized to derive principal eigen values and eigen vectors. Maps of diffusion metrics
namely Fractional anisotropy (FA), relative anisotropy (RA), mean diffusivity (MD),
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parallel diffusivity (λ||) radial diffusivity ( λ⊥ ), Westin’s linear (CL) and planar (CP)
index were obtained. Virtual neuronal fibers were reconstructed using the fiber
assignment by continuous tracking (FACT) algorithm29 , described in detail elsewhere.
Fiber tracking parameters were initiated from every voxel with FA = 032, threshold for
termination was 0.232 and a bending angle of 41o.

After these preliminary processing steps, all subjects CST fiber tracts on both left
and right sides were reconstructed after Wakana et al32 by placing first ROI caudally in
the cerebral peduncle (CP) and the second rostrally just below the primary motor cortex.
Along the CST, four regions of interest (ROIs) were identified to evaluate the
pathophysiological changes in ALS. These are cerebral peduncle (CP), internal capsule
(IC), top of the lateral ventricle (LV) and subcortical motor cortex (MC). DTI metrics
mentioned above were measured for each subject in these ROIs and were compared
against controls and also between the patient subgroups. We randomly selected 19 of 68
subjects to study distortion effects caused by susceptibility artifacts along the CST. In
these 19 subjects diffusion tensor matrix and the diffusion metrics were calculated for
both conditions i.e. with and without field map corrections. ROIs of same size and shape
were applied at CP and MC levels while reconstructing the CST in both with and without
field map corrected images. The number of CST fibers, CST fiber volume and average
FA along the entire CST were evaluated to determine the effects of susceptibility artifacts.
Statistical comparisons for each of the DTI metrics across control and patient groups
were carried out using SPSS 16.0. Based on data meeting the assumptions of ANOVA
one of the following statistical methods was used with a significance level of p < 0.05; a)
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one-way ANOVA followed by Tukey’s post hoc test was carried out when the
assumptions of both normality and equal variance were met. b) On the other hand only if
the equal variance assumption was violated Welch ANOVA followed by Dunnett T3 post
hoc test was employed. c) When both normality and equal variance assumptions were
violated Kruskal-Wallis non-parametric approach followed by Bonferroni correction of
Mann-Whitney test was used. The effects of susceptibility artifacts was evaluated by
employing Student T-test or Mann-Whitney U test based on data meeting the assumptions
of normality and equal variance.

3.6 Results
The statistical group comparison results along different levels of CST for FA, RA, MD,
axial and radial diffusivities are given in Figures 16 to 20.

3.6.1

Fractional anisotropy

FA values were found to be reduced in all ALS groups when compared with the
controls. FA values showed significant difference between control and the CST
hyperintense, CST non-hyperintense and dementia groups at the level of IC. In addition
to this, the ALS-dementia and CST hyperintense groups were significantly different from
controls on the left CP. On the other hand FA values were significantly different between
control and classic ALS groups only at the level of CP. Dementia patients were
significantly different from the controls in CP and IC levels. Besides this, there was no
significant difference among the ALS sub groups at any levels of the CST.
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3.6.2

Relative anisotropy

Similar to FA results, RA values were found to be decreased in ALS patients when
compared to controls. RA results were similar to FA values except that there was no
significant difference between control and CST hyperintense and dementia groups on the
left CP.
3.6.3

Axial and Radial diffusivities

In general, axial diffusivity values were reduced in ALS patients compared to
controls. Axial diffusivity, on the other hand, showed significant differences between
control and CST hyperintense, CST non-hyperintense and classic ALS groups mainly in
the left IC; however with CST non-hyperintense group, the difference was significant on
the right side too. Between ALS subgroups, axial diffusivity was significantly different
between CST non-hyperintense group and dementia group at the level of IC. On the other
hand, between classic ALS and ALS-dementia groups, significance was observed only in
the right MC. Radial diffusivity values, on the other hand, were elevated in ALS patients
compared to controls, and were almost identical to FA values at the IC level; at the CP
level, radial diffusivity also reached significance between CST non-hyperintense and
classic ALS groups. In addition, radial diffusivity was significantly different between
control and ALS groups in the left LV, i.e. CST hyperintense and CST non-hyperintense,
whereas significant differences were observed in both right and left LV levels between
control and dementia patients.

3.6.4

Mean diffusivity

In general, MD values were elevated in ALS patients when compared to controls.
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MD was significantly different between control and CST hyperintense and ALS-dementia
groups in the left IC; the ALS-dementia group also showed significance at the LV level.
Between ALS groups, comparisons resulted in significant differences between dementia
and CST hyperintense, CST non-hyperintense and classic ALS groups in the right LV. In
addition to this, the ALS-dementia group was also significantly different from CST nonhyperintense and classic ALS groups in the left IC.
3.6.5

Susceptibility artifact measures

Total number of CST fibers, fiber volume and average FA values along the entire
CST were measured in order to evaluate susceptibility artifacts. These results are given in
Table 3. No significant difference (p>0.05) was observed in any of the above measures
obtained with or without field map correction.

a)
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b)

Where CP- Cerebral peduncle, IC –Internal capsule, LV- Top of lateral ventricle, MC-Sub cortical

b)

motor cortex.

Significance at p<0.05

Figure 16: FA results at various levels of CST a) Right CST and b)Left CST.
revealing significant difference between groups at p<0.05
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a)

b)
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Where CP- Cerebral peduncle, IC –Internal capsule, LV- Top of lateral ventricle, MC-Sub cortical
motor cortex.

Significance at p<0.05

Figure 17: RA results at various levels of CST a) Right CST and b)Left CST
revealing significant difference between groups at p<0.05

a)
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b)
Where CP- Cerebral peduncle, IC –Internal capsule, LV- Top of lateral ventricle, MC-Sub cortical
motor cortex.

Significance at p<0.05

Figure 18: MD results at various levels of CST a) Right CST and b)Left CST
revealing significant difference between groups at p<0.05
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a)

b)
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b)
Where CP- Cerebral peduncle, IC –Internal capsule, LV- Top of lateral ventricle, MC-Sub cortical
motor cortex.

Significance at p<0.05

Figure 19: Axial diffusivity results at various levels of CST a) Right CST
and b)Left CST revealing significant difference between groups at p<0.05

a)
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b)
Where CP- Cerebral peduncle, IC –Internal capsule, LV- Top of lateral ventricle, MC-Sub cortical
motor cortex.

Significance at p<0.05

Figure 20: Radial diffusivity results at various levels of CST a) Right CST
and b)Left CST revealing significant difference between groups at p<0.05
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3.7 Discussion
3.7.1

Fractional anisotropy

FA results seen in this study at the level of the IC agree well with previous ALS
studies8-10, 13, 15, 33. Absence of significant differences between CST hyperintense and
non-hyperintense groups in all the DTI metrics suggests that divergent pathologies may
exist in the extracranial (e.g.spinal cord) axons of these two groups rather than
degeneration of the perikaryon in motor cortex or extracranial CST. One of the reasons
we didn’t observe any significance at the MC level between CST hyperintense and nonhyperintense groups might have resulted from the truncation of CST below MC in 7 of 13
patients in the former group and 7 of 21 in the latter group. However, this was not
observed in the ALS-dementia or in control subjects, however in the classic ALS
group,only 2 of 12 subjects’ left CST tracts were truncated below the MC level. Since
acquisition and post-processing of images in all groups were performed identically, we
believe the extent of CST degeneration is greater in these patients than in the others.
Figure 21 a) shows the CST in a control subject and figure 21 b) shows absence of CST
in MC in a UMN predominant CST hyperintensity patient. Further studies are required in
order to validate these findings.
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b)

a)

Figure 21: Sagittal view of FA color map shows localization of using subject’s
own tractography-derived CST a) control b) UMN predominant
hyperintense patient

3.7.2

Relative anisotropy

Jacob et al33 observed reduction in RA values in the pyramidal tract in one UMN
ALS patient before and after a 9 month follow-up, while no significant difference was
reported in two patients with LMN and bulbar symptoms. In our study, RA values were
significantly different between the classic ALS group and controls in the CP, whereas
comparison between other ALS groups (CST hyperintense, non-hyperintense and
dementia groups) and controls significance was reached only in the IC. Since the study
paradigms are different and a very small population of ALS patients was studied by Jacob
et al33 the results are difficult to compare.
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3.7.3

Axial and Radial diffusivities

Christian Beaulieu18 showed that changes in FA values can result from either
decreased axial diffusivity, increased radial diffusivity, or both. He also demonstrated that
two subjects can have the same FA values but individual axial and radial diffusivity
values may differ. Beaulieu18 also shows some encouraging evidence from animal and
human studies suggesting that axial diffusivity physiologically corresponds to axonal
degradation and radial diffusivity to myelin degradation. However, these interpretations
should be interpreted with caution because they are likely over-simplifications and further
studies are warranted to confirm these above findings. Nonetheless, The above factors
suggest that a more accurate physiological insight can be obtained by using axial and
radial diffusivities.

Axial diffusivity values in our study reached significance only at the IC level
between control and ALS groups whereas, Wong et al34 showed significant increase only
in corona radiata. In our study, we observed a decreasing trend in axial diffusivity values
from the CP to MC in both control and ALS patients. Discrepancies in these results may
be due to the following factors: a) ALS group studied by Wong et al included both bulbarand limb-onset patients, b) small sample size (only 14 ALS subjects), c) less number of
diffusion weighting directions in both studies (Wong et al employed 6 directions, ours 12
directions) whereas studies by Jones et al35 and Ni et al36 recommend 30 directions for
robust estimation of individual eigen values λ1, λ2 and λ3, d) significant partial volume
effects from thicker slices (Wong et al’s 5 mm thickness, ours 4 mm), e) compared to
manual ROI tracing, tractography methods result CST identification which is more
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accurate, more reproducible37,

free from operator bias, and less time intensive.

Tractography methods on the other hand are sensitive to signal to noise ratio, anatomical
variability between subjects6 and resolution. An interesting finding in our study was that
axial diffusivity revealed significant differences between the ALS subgroups which was
not observed with FA or RA. Axial diffusivity values were significantly elevated in the
ALS-dementia group at the IC level when compared with the CST hyperintense group,
and at the right MC level when compared with classic ALS group.

Radial diffusivity values revealed some variation in our ALS patients when
compared to controls, being elevated in the MC, reduced in IC and increased in CP. On
the other hand, Wong et al showed a decreasing trend rostrocaudally from the corona
radiata to the CP. They failed to observe significant differences between ALS patients and
control subjects whereas in our study radial diffusivity not only showed significant
difference between these groups, but we also found it to be significantly elevated in the
classic ALS group when compared with UMN predominant CST non-hyperintense group.
An interesting point here is that radial diffusivity values between control and UMN
predominant CST hyperintense, UMN predominant CST non-hyperintense and ALSdementia groups were not significantly different at CP level but were more rostrally, i.e.
at IC and LV levels. In contrast, control and classic ALS groups showed significant radial
diffusivity differences only at the CP level and not higher up along the CST. Values were
significantly higher in the classic ALS group, when compared to UMN predominant CST
non-hyperintense group suggesting a more pronounced CST degeneration in the classic
ALS patients (who have prominent LMN degeneration) at the CP level when compared to
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the UMN group. Diffusion metrics FA, RA also showed significant differences between
control and classic ALS groups at the CP level but not rostrally along the CST. Taken
together, our findings suggest that axon degeneration in classic ALS patients (who have
prominent LMN signs) may be more caudal (e.g., at the spinal cord level) when
compared with UMN group (who do not). To our knowledge, this is the first MRI study
using tractography to evaluate axial and radial diffusivities along the CST in large
subgroups of ALS patients.

3.7.4

Mean diffusivity

In general MD values in ALS patients were found to be elevated at all the levels
of the CST when compared with controls. However, MD values reached significance
more rostrally i.e. in LV and IC levels between control and ALS groups and also among
ALS subgroups. Between group comparisons showed significant increases in MD values
in the left IC of ALS-dementia patients when compared with classic ALS and UMN CST
non-hyperintense groups. Our results at the IC level agree with other ALS studies7, 38, 39.
However, Yin et al39 in their study group of ALS patients (6 limb onset , 2 bulbar onset)
found no significant differences in MD values at IC.

3.7.5

Westin’s linear (CL) index and planar index (CP)

The values of DTI metrics along the CST at the LV level were found to be slightly
different from those of the other 3 ROIs. In our control subjects, axial diffusivity values
were lowest in LV region compared to those at CP, IC & MC levels, and radial diffusivity
values were higher in LV region compared with other 3 ROIs. Since the LV ROI is in a
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region where superior longitudinal fasciculus fibers cross with the CST, we explored this
using Westin’s linear index (CL) and planar index (CP)19,

20

. Westin’s index is a

geometrical index which measures the shape of the diffusion tensor ellipsoid against
scalar measures like FA. Westin’s CL (where λ1>>λ2≈ λ3) measures uniformity of tracts in
a voxel whereas Westin’s CP (where λ1≈ λ2 >> λ3) indicates fiber crossings. If there is
fiber crossing, the planar index (CP) will have high values (close to 1) whereas the linear
index (CL) will be low (close to 0). Table III gives Westin’s CL and CP (left and right
side combined) for all the 4 ROIs in control subjects. Average linear values (CL) were
found to be lower in LV region when compared with other 3 ROIs, on the other hand
planar values were comparatively elevated in LV. Figure 22 a) and (b) shows changes in
CL values at the level of cerebral peduncle and in LV. Figure 23 (a) and (b) are the color
maps of CL at cerebral peduncle and LV obtained by using CL map and first eigen vector.
High linear index and low planar values in CP and IC agree well with the anatomical
structure of CST in these regions (i.e. highly coherent and uniform), so reduced linear
index and slightly elevated planar index in LV indicates that there may be more than one
fiber population in this region.
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Table III: Average values of Westin’s linear and planar indices at different
levels of CST
Westin’s Index

CP

IC

LV

MC

Linear index (CL)

0.64

0.68

0.41

0.46

Planar index (CP)

0.09

0.12

0.19

0.15

CP-cerebral peduncle, IC-internal capsule, LV-top of lateral ventricle, MCsubcortical motor cortex

a)

b)

Figure 22: Transverse image of a control subject’s CL map a) Cerebral
peduncle level, b) top of lateral ventricle level
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a)

b)

Figure 23: Transverse image of a control subject’s CL color map a) Cerebral
peduncle level, b) top of lateral ventricle level

3.7.6

Evaluating susceptibility artifacts in CST

Figure 24 (a) and (b) shows DW images before and after field map correction. It
can be seen from Table IV that parameters number of fibers, fiber volume and average FA
values remain almost identical in CST between with and without field map correction
procedures which suggests that CST is not affected by susceptibility artifacts. Under
regular conditions, field maps were not acquired as part of clinical DTI protocols. Since
most of the clinical studies employ SS-EPI sequence we believe that susceptibility
artifacts need to be corrected before employing these images for any research purpose
because to our knowledge there are no post-processing techniques available today to
correct for these distortions. However, the results of this study indicate that if CST is the
primary region of interest then field map acquisitions may not be required.
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Table IV: Measures to evaluate susceptibility artifacts in CST
Measure

Number
of fibers

Fiber volume
(number of
voxels)

With
field
map

With
field
map

Mean±S 48.82
D
±48.7
9
Median 34.5

Quartile 14,
s
(1st, 63.50
3rd)
MannWhitney
U test /
T-test

Without
field
map
42.58±4
6.44

Witho
ut
field
map
195.95 183.36
±160.4 ±157.7
2
1

23

12,
63.50

158.5
101.25
,
230.25

P=0.395

149.5
105.25
,
191.75

FA

With
field
map
0.50
2±0.
05
0.49
7
0.46
5
0.53
0

P=0.617
963

SD- standard deviation
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With
out
field
map
0.50
1±0.
05
.499
0.47
4,
0.53
0
P=0.

a).

b).

Figure 24: Transverse image showing susceptibility artifacts in frontal
regions of the brain a) before correction, b) after correction in one of our subjects

In essence, the discrepancies seen in results between our study and the ALS literature
can be due to some of the following factors; a) tractography method is sensitive to signal
to noise ratio, anatomical variability between subjects and resolution. According to Mori6,
tractography method gives 30% variability even when used within control subjects. b) On
the other hand ROI approach suffers from operator bias, poor reproducibility and is time
consuming. c) Studies35,

36

have shown that at least 30 directional measurements are

required for robust estimation of eigen values whereas only 12 directional DTI data was
acquired in our study (due to scanner software constraints). d) Thicker slices of 4 mm in
our study will contribute of partial volume effects and anisotropic voxels may affect
tractography results.
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3.8 Conclusion
One caveat is that comparing and contrasting results of this study with others may be
inaccurate because of differences in used DWI schemes and sequences, number of
gradient directions, and methods to process DTI images. However, similarities between
results from this and previous DTI studies are changes in FA and MD values at the level
of internal capsule in ALS patients compared to controls. This study shows that axial and
radial diffusivities provide additional information when compared to anisotropy measures
FA or RA. To our knowledge, this is the first study to assess diffusion metrics in a large
group of ALS patients after being categorized into different subgroups, and to
demonstrate that CST measures remain unaffected by susceptibility artifacts. This study
also shows that subcategorizing ALS patients by clinical features (e.g., extent of UMN
and LMN dysfunction) reveals group-specific differences in DTI metrics which suggests
variance in ALS pathogenesis, increasingly considered a syndrome rather than a single
disease. Finally, by showing that DTI measures along the CST are unaffected by
susceptibility artifacts, additional field map correction sequences would not be necessary
for clinical imaging protocols, thereby saving time and data storage space. However,
future studies with larger sample sizes of subgroups and using robust DW acquisition
schemes are warranted to confirm our findings.

3.9 Limitations and Future scope
The main limitation of this study is the low directional DTI data (12 directions),
anisotropic voxels which result in suboptimal signal to noise ratio, and thicker slices
contributing to partial volume effects. Future studies will utilize probabilistic tracking
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instead of the deterministic approach (used in this study) to reconstruct the entire CST to
assess the reason for its truncation rostrally in some ALS patient subgroups. This will
reveal whether the truncation is due to differences in the disease process and provide
novel insights into pathogensis. Adding more control subjects will increase the power of
the statistical tests. Future comparisons of DTI and post-mortem histopathology in the
same patient will allow radiopathologic correlation of tissue pathology underlying the
radiographic changes, including CST hyperintensity.

Next study addresses assessment of neuronal integrity in ALS patients using high
resolution T1 weighted images . Quantitative measurements techniques such as voxel based
morphometry and cortical thickness were used to assess grey matter volume changes
especially in ALS patients when compared to controls.
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CHAPTER IV
Voxel Based Morphometry and Cortical Thickness in ALS

4.1 Voxel Based Morphometry
4.1.1

Introduction

Although ALS has been traditionally regarded as purely a motor neuron disease,
there is increasing awareness of extramotor involvement, especially of brain regions
subserving cognition and behavior1. Unlike dementia in Alzheimer’s disease, the
cognitive impairment seen in some patients with ALS affects predominantly
frontotemporal areas and is known as frontotemporal dementia (FTD). A recent discovery
that nuclear TDP-43 protein is mislocalized to the cytoplasm in patients with ALS, FTD,
or both is the first pathobiologic link between these two conditions2.

2,3-FDG positron emission tomography (PET) studies of ALS patients with coexistent dementia have revealed reduced cerebral blood flow in frontotemporal regions
which indicates neuronal hypometabolism, as shown in figure 25. When dementia is
advanced, cerebral atrophy usually is detected on MRI.
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In this study we aim to understand the extent of extramotor involvement in ALS
patients by assessing the degree of atrophy in gray matter (GM) structures in different
patient subgroups using 3D high resolution T1-w images.

Figure 25: [18F]2-fluoro-2-deoxy-D-glucose PET brain imaging of an ALS
dementia patient showing reduced metabolism in both temporal lobes
(arrowheads) and inferior frontal lobes (arrowheads).

Conventional MRI of ALS patient brain usually shows little if any atrophy,
although this is likely a misrepresentation because of the qualitative nature of these
studies3. Quantitative assessment of high resolution 3D MR images will allow more
precise measures of GM and white matter (WM) loss in ALS. Post mortem studies have
revealed various forms of cortical pathology in ALS ranging from obvious neuronal loss
to neuronal shrinkage but no loss or no obvious pathology, all in the setting of
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proliferation and hypertrophy of neuroglia, which add to the complexity of the degrees of
cortical atrophy in ALS.

Voxel-based morphometry (VBM) analysis allows objective and automated
detection of structural differences in brain tissue (e.g. atrophy) between subjects after
normalizing for random shape differences4. Being an unbiased assessment, it can be used
for exploratory analyses when no a priori knowledge of distribution in pathology is
available. For example, atrophy in ALS may occur outside motor regions, especially
when patients have additional dementia, making VBM-based morphometry an ideal
approach to studying this. Once the patient’s brain is fitted to common brain template
(e.g., study-specific template created from a sub-group of patients under study) which
normalizes for any random variation between brains shapes and sizes, it is smoothed and
a statistical parametric map generated of grey matter from which significant differences
in tissue amounts are identified between patient and control brain templates.

Atrophy measures in ALS GM and WM throughout the brain will also assess the
growing belief that ALS is a multisystem disease and not restricted to motor regions,
even in patients without frontotemporal dementia (FTD)1, 5, 6. Ellis and colleagues were
the first to apply VBM to ALS patient brains6. Their study using T2-weighted images
showed significant differences in GM and WM volumes between ALS and control
subjects and also between ALS with limb-onset and bulbar-onset groups. Using VBM,
Chang and collaborators studied GM and WM changes in ALS patients with (n=10) and
without (n=10) FTD when compared to control subjects (n=20)7. No WM volume
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change was observed either between ALS subgroups or between ALS and controls
subjects. Distribution of GM volume change was similar between ALS with and without
FTD except that ALS-FTD patients had more atrophy in motor, premotor and frontal and
posterior thalamus. Based on these observations, they concluded that a continuum of
cortical atrophy exisits between these two ALS groups. Abrahams and colleagues studied
GM and WM changes in ALS patients with and without cognitive impairment which was
assessed based on verbal fluency test5. ALS patients with FTD were excluded from their
study. ALS with cognitive impairment showed extensive atrophy changes in both motor
and in extra- motor (frontal and temporal) WM structures when compared to both
controls and unimpaired ALS patients. However, no significant change was observed in
any of the GM structures. They also reported that the above changes were consistent with
their PET studies suggesting that cognitive impairment may be more common in ALS
patients and not restricted only to ALS patients with dementia. Mezzapesa and
collaborators on the other hand, studied atrophy changes in 9 healthy and 16 ALS patients
without any cognitive deficits8. VBM results showed significant (p<0.001, uncorrected)
reductions in gray matter volume in temporal and frontal lobes of non-demented ALS
patients compared to controls, although WM volume loss was not observed.

4.1.2

Limitations of previous studies

Large slice thickness (e.g., 3 mm in studies by Abrahams et al5 and Chang et al7)
contributes to partial volume effects; voxel resolution of 1×1×1 mm is highly
recommended for VBM studies7 . Absence of significant differences in clinical measures
between ALS-FTD and ALS groups in the study by Chang and colleagues raises concerns
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regarding criteria used to classify ALS patients into subgroups7. The study by Ellis and
collaborators, on the other hand, employed T2-weighted images, which suffer from poor
tissue contrast between GM and WM structures6. Inadequate information was provided
by Abraham and colleagues regarding level of significance and multiple comparisons,
making assessment of their methodology difficult5. In addition, Mezzapesa and
collaborators identified p<0.001 but this was uncorrected for multiple comparisons8. This
raises significant statistical concerns considering VBM tests the same hypothesis in every
voxel and correcting for multiple comparisons is therefore mandatory. Furthermore, the
aforementioned studies all employed Gaussian random field theory based statistical
comparisons for which the analyzed data should have had Gaussian distribution.
However, several studies9-11 have shown that these criteria are difficult to verify and meet
due to inherent noise in the data and so recommend non-parametric permutation based
analyses for statistical comparisons. Therefore, the discrepancies seen in the above
studies can be attributed to various factors, including: methodological differences (e.g.,
imaging parameters, statistical analyses) and combining patients with differing clinical
presentations and stages of disease, assuming that they all manifest the same disease.

4.1.3

Aim

Earlier studies provide ample evidence that ALS is a multifactorial entity (i.e.
processes like neuronal degeneration, gliosis) causing effective changes in cerebral (e.g.,
GM and WM) volumes. Therefore, we aimed to measure changes in volume of GM
structures due to atrophy in our ALS-FTD patients primarily, but also in our other ALS
patient subgroups.
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4.1.4

Hypothesis

It is hypothesized that cerebral GM volume is significantly different between
control individuals and ALS patients and also between the ALS subgroups themselves.
We also hypothesize that if GM volume is lower in ALS patients compared to control
subjects, onset of neurodegeneration in ALS is in the perikaryon (cell body), as a
neuronopathy. If, on the other hand, no change is detected in cerebral GM volume of ALS
patients compared to controls, the disease process is a “dying-back” (retrograde
axonopathy) phenomenon.
4.1.5

Method

4.1.5.1 Imaging protocol
Magnetization prepared rapid gradient echo (MPRAGE) sequence was used to
acquire T1 weighted images on a 1.5 T system (Siemens Symphony, Erlangen, Germany)
in 9 control subjects (6 men, 3 women), and 72 ALS patients: 13 UMN-predominant with
CST hyperintensity (8 men, 5 women), 25 UMN-predominant without CST
hyperintensity (16 men, 9 women), 14 typical ALS with mixed UMN and LMN signs (9
men, 5 women), and 20 with ALS-FTD (5 men, 15 women,). This high resolution 3D T1weighted MPRAGE sequence provided good GM-WM contrast14. MPRAGE sequences
are less sensitive to pulsation artifacts because of shorter TEs and saturation effects of
flowing blood in the whole excitation volume11. The following MPRAGE parameters
were used for pulse sequence: TR = 1970 ms, TE = 4.38 ms, number of averages = 1, flip
angle =10o, TI =1100 ms, scan time = 6.45 minutes, and imaging: number of slices = 160,
contiguous, slice thickness = 1 mm, in-plane resolution = 0.9×0.9 mm.
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4.1.5.2 Data Processing
An optimized VBM approach of Good and colleagues was adopted12 with all
processing steps carried out using openware FSL (http://www.fmrib.ox.ac.uk/fsl/). Data
processing was divided into four major steps: (1) Brain extraction in all the subjects using
fsl_vbm_1_bet routine, with manual editing to remove any remaining non brain regions;
brain extracted images were segmented into WM, GM and CSF probability maps. (2)
Creation of a study specific GM template13 by registering a subset of subjects from
control and ALS groups into the MNI152 space (to avoid bias during the registration
process). 3) GM template was created were registration of all subjects to the studyspecific GM template using both linear and non-linear registration methods; GM volumes
were concatenated and smoothed (to increase singal-to-noise ratio) using a Gaussian
kernel of 3 mm with a full-width half-maximum (FWHM) of ~7 mm. (4) Application of
permutation based non-parametric statistics to the data set to identify significant
differences in GM volume between control subject and ALS groups. As mentioned above,
non-parametric statistical approaches are recommended in the literature8-10 because the
data often violates Gaussian distribution. A general linear model (GLM) was adopted to
compare differences in GM volume between 4 different ALS subgroups and the control
group. A p<0.05 corrected for multiple comparisons using false discovery rate (FDR) was
considered the level of significance.
4.1.6

Results

Significant differences were detected in motor and extra motor regions only
between control and ALS-FTD subjects, as shown in figure 26 below. Cortical regions
significantly atrophic in ALS-FTD patients compared to controls are shown in figure 26
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to be: frontal and temporal lobes, occipital fusiform gyrus, lingual gyrus, lateral occipital
cortex inferior division, inferior temporal gyrus temporooccipital part, temporal occipital
fusiform cortex, lateral occipital cortex superior division and superior parietal lobule. The
extra motor regions of inferior temporal gyrus, fusiform gyrus, and lingual gyrus have
cognitive functions30, including face recognition30, word recognition, and color
information processing. The hippocampus in the temporal lobe is primarily responsible
for long-term memory30. Non-motor frontal and prefrontal areas are responsible for
executive functions, behavioral and emotional regulation. GM volume changes in ALSFTD supports our hypothesis that these patients exhibit early neurodegeneration in the
perikaryon (as a neuronopathy) with early anterograde degeneration affecting the entire
axon with wallerian degeneration . No other ALS subgroup showed GM volumes that
were significantly different from control individuals, consistent with a “dying back”
axonopathy of motor pathways and relative preservation of the perikaryon until later in
the disease process. Like our findings, Sage et al13 and Abrahams et al5 also did not
identify significant differences in GM volume between control subjects and ALS patients
without dementia whereas other studies did7,8. Discrepancies in results between our study
and the latter ALS studies may be due to the following: a) potential misclassification by
Chang and collaborators7 of ALS patients with and without dementia considering both
groups had similar clinical symptoms; b) use of uncorrected statistics (p<0.001) by
Mezzapesa and colleagues8, which will lead to large Type I error; c) employment of
Gaussian random field (GRF) theory based statistical analysis by both of these groups7,8,
while we used a non-parametric permutation based approach.
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Figure 26: Regions which showed statistical significance between control and
ALS dementia were shown by superimposing them on MNI brain template

4.1.7

Conclusion

Absence of GM changes in non-demented ALS patient subgroups supports our
hypothesis that such patients may experience a “dying back”axonopathy of the UMN
with only late perikaryon degeneration and loss. In contrast, GM loss in ALS-FTD
patients suggests an early loss of perikaryon (neuronopathy) with resultant global
anterograde wallerian degeneration.
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4.1.8

Limitations and Future Scope

Since previously published ALS VBM studies widely employed GRF-based
statistical analyses, a comparison of these and permutation based statistics in same
sample of patients and controls would determine whether discrepancies between different
studies are due to the statistical procedures utilized. A larger sample study, especially of
the control group, would confirm our findings.
A better understanding of the pathophysiological mechanisms in ALS can be
achieved by combining GM VBM results with brain 2,3-FDG PET data in order to
correlate structural and functional changes. In addition, combination of VBM and DTI
studies would help validate the dying-back axonopathy vs. early neuronopathy sites of
degeneration in ALS patient subgroups. Confirmation and validation of our findings
could be achieved by post-mortem histopathological studies of such patients showing the
aforementioned VBM changes.
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4.2 Cortical Thickness in ALS
4.2.1

Introduction

The human cerebral cortex has a complex organization of layers and columns: a)
six horizontal layers (I-VI) each having a unique cellular organization and synaptic
connections, b) multiple vertical columns (comprised of neurons and surrounding
neuropil) for each single function and c) subdivision of each column into hypercolumns,
which combine different functional columns. Therefore, pathological changes of cortical
neurons (e.g. shrinkage or loss) and surrounding neuropil resulting in physiologic
dysfunction may affect column length (e.g. reduction), which in turn alters cortical
thickness (e.g. reduction). Therefore, a physical and functional change in the cortical
neuronal circuitry is reflected by altered cortical thickness (usually reduced). Thinning of
the cortex due to pathological changes has been widely reported in various neurological
disorders namely; Alzheimer’s disease15, Huntington’s disease16 and multiple sclerosis17.
Voxel based morphometry (VBM) described in the previous section quantitatively
assesses GM volume changes in the brain using high resolution T1-weighted images.
However, VBM provides only part of the information because volume change can result
either from changes in cortical thickness or cortical surface area or both and
differentiating between the two is not possible with VBM. In addition, estimation of GM
volume by VBM includes both cortical thickness and cortical foldings (gyri and sulci)
such that adjacent gyri can be mistaken as a single GM area, as shown in figure 27,
resulting in erroneous high GM concentration18. Cortical thickness measurements
overcome this error, as well as providing additional information on the possible
pathophysiological changes in ALS, as discussed above.
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a)

b)

Figure 27: a) Cartoon of adjacent gyri appearing connected to each other, b)
MR image in which this gyral foldings (adjacent gyri abutted) appears as a single
large GM area (indicated by cross hair).
Adapted from Jason Lerch Master’s thesis proposal

An earlier study reported shrinkage in the surface area of precentral gyri of ALS
patients although without significant differences between ALS and control subjects on
group comparisons3. A stereological study surprisingly found no abnormalities in post
mortem ALS brain tissue after estimating total number of cortical neurons, measuring
cortical thickness, as well as surface area and volume of neocortex, white matter and
central grey nuclei19. Measurements in the two aforementioned studies were performed
manually which is not only time consuming but also introduces operator bias and poor
reproducibility. Furthermore, huge errors in thickness measures will result if the image
plane is not perpendicular to the cortical surface, as pointed out by Fischl and Dale20 .As
shown in figure 28 below, measuring cortical thickness in the same location (identified by
green dot) but in two different planes will result in a higher value in the coronal view as
compared to axial view. This discrepancy occurs because cortical thickness is measured
90

parallel to the imaging plane in the coronal view but perpendicular to it in the axial view.
In their earlier study, Kiernan and Hudson identified six potential measurement errors of
cortical surface area by MRI: partial volume, head tilt, plane of view, contiguous slices,
intensity manipulation, and magnetic inhomogeneities3.

Green dots indicate the same
cortical location but in two
different planes demonstrating
how thickness measures will be
greater in the coronal view (a)
than in the axial view (b).

a)

b)

Figure 28: Cortical thickness of the same cortical region is over estimated
when measured in the coronal plane (a) compared to the axial plane (b) where it is
more accurately represented
Adapted from Fischl, (2000).

The aforementioned drawbacks of manual cortical thickness measurements can be
essentially removed if automated image processing techniques are employed. Therefore,
a fully automated cortical thickness measurement software (developed by Fischl and
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Dale20) was used in this study to assess cortical thickness in our ALS patient subgroups.
Multiple earlier studies have amply demonstrated that ALS is a multicellular
disorder (i.e. neuronal shrinkage and/or loss, gliosis) causing degenerative changes in
GM structures
4.2.2

Aim

Our VBM study showed significant GM volume loss in only ALS-FTD dementia
patients but not in the other ALS subgroups, compared to control individuals. Therefore,
the present analysis of cortical thickness aims to determine whether the GM volume
reduction by VBM is due to decreased cortical surface area, cortical thickness, or both.

4.2.3

Hypothesis

It is hypothesized that cortical thickness is significantly different between control
and ALS patients, especially the ALS-FTD subgroup, and also within the ALS subgroups
themselves. We also hypothesize that if significant changes in cortical thickness are
observed between ALS patients and control subjects, then the neurodegeneration
mechanism in the ALS subgroup may be a neuronopathy affecting the neuronal perikayon.

4.2.4

Method

4.2.4.1 Imaging protocol
Magnetization prepared rapid gradient echo (MPRAGE) sequence was used to
acquire T1-weighted images on a 1.5 T system (Siemens Symphony, Erlangen, Germany)
in 11 control subjects (8 men, 3 women) and 72 ALS patients: 13 UMN-predominant
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with CST hyperintensity (8 men, 5 women), 25 UMN-predominant without CST
hyperintensity (16 men, 9 women), 14 typical ALS with mixed UMN and LMN signs (9
men, 5 women) and 20 with ALS-FTD (5 men, 15 women). This high resolution 3D T1weighted MPRAGE sequence provided good GM-WM contrast14. MPRAGE sequences
are less sensitive to pulsation artifacts because of shorter TEs and saturation effects of
flowing blood in the whole excitation volume12. MPRAGE pulse sequence parameters
were: TR = 1970 ms, TE = 4.38 ms, number of averages = 1, flip angle =10o, TI =1100
ms and scan time = 6.45 minutes; imaging parameters were: number of slices = 160,
contiguous, slice thickness = 1 mm, in-plane resolution = 0.9×0.9 mm.
4.2.4.2 Data Processing
Cortical thickness measures were carried out using Freesurfer, an openware
(http://surfer.nmr.mgh.harvard.edu/).

Image processing steps begin with motion

correction and skull stripping based on hybrid watershed /surface deformation
procedure21. The images are then registered to a Talairach brain template, segmented for
subcortical WM and GM structures22, and intensity normalized for uniform intensity
values across the WM and GM structures23. After intensity normalization, a tessellation
step estimates the GM-WM boundary and subsequent automated topology correction24,25.
The GM-WM and GM-cerebrospinal fluid (GM-CSF) boundaries are optimally placed
using surface normalization and intensity gradients20,26. After cortical models are
completed, deformable procedures are performed for further processing and analysis like
surface inflation and registration to a spherical atlas27. Both intensity and continuity
information from the entire 3D MR volume is used to produce representations of cortical
thickness and thickness is measured as the closest distance from GM-WM to GM-CSF
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boundary at each vertex on the tessellated surface20 as shown in figure 29 below. Because
the maps are not restricted to voxel resolution of the original data they are capable of
detecting submillimeter differences between groups.

Figure 29: MPRAGE image showing how cortical thickness (arrows) is
determined between GM-WM (broken yellow line) and GM-CSF (broken red line)
boundaries.
Adapted from Fischl, Tutorial slides.

4.2.5

Results

High resolution 3D T1-weighted images from all control and ALS subjects were
processed as described in the data processing section. This analysis provides additional
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information on the changes in GM structures, as discussed previously (i.e. volume = area
* thickness). Cortical thickness, surface area, and volume were compared between
control and ALS subgroups using the GLM statistical model with FDR at p< 0.05 for
multiple comparisons. Significant differences in cortical thickness were observed only
between control subjects and the ALS-FTD subgroup, as shown below in figure 30.
These regions were mapped based on the Desikan28 atlas. Table V below gives the
Talairach coordinates and corresponding cortical regions, which were significantly
different between the control and ALS-FTD groups. No significant differences in cortical
thickness were observed between control and any of the other ALS subgroups. Cortical
surface area and volume were also compared between control subjects and ALS patients.
No significant differences were observed in cortical surface area but cortical volume
(Note that cortical volume here refers to volume of the cortex whereas in VBM study the
volume measured has both cortical and sub cortical GM structures) was significantly
different between control and only ALS-FTD groups, as shown in figure 31; no
significant differences in cortical volume were observed between control individuals and
any other ALS subgroups. Table VI below gives Talairach coordinates of regions which
were significantly different between control and ALS-FTD groups for both cortical
volume and thickness metrics. Therefore, these results indicate that decreased cortical
volume in the ALS-FTD patients (found by VBM) is due to reduced cortical thickness
and not reduced cortical surface area.
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Figure 30: Colored regions (heat map) indicate regions of statistical
significance (p<0.01) superimposed on average inflated template showing cortical
thinning in ALS-FTD patients relative to controls results are projected onto the left
hemisphere, laterally (top left image), medially (bottom left image) and right
hemisphere, laterally (top right image), medially (bottom right image). Color bar is
scaled in units of log 10 (p)
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Figure 31: Colored regions (heat map) indicate regions of statistical
significance (p<0.01) superimposed on average inflated template showing reduction
in cortical volume in ALS-FTD patients relative to controls results are projected
onto the left hemisphere, laterally (top left image), medially (bottom left image) and
right hemisphere, laterally (top right image), medially (bottom right image). Color
bar is scaled in units of log 10 (p)
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Table V: Talairach coordinates and regions which are significantly different
between control and ALS dementia groups using cortical thickness measure
Talairach coordinates
Cortical
regions
(vertex of cortical region) (X, significantly affected in ALS
Y, Z)
dementia
-37.55, 42.61,4.82
rostral middle frontal
-46.14, 30.35, -3.23

lateral orbitofrontal

-40.43, 38.91, -12.20

pars orbitalis

-32.81, 21.55, -17.09

lateral orbitofrontal

-50.36, 15.76, 16.36

pars opercularis

-34.99, 9.32, 31.24
-50.57, 3.39, 27.25

caudal middle frontal
precentral gyrus

-59.25, -15.11, 17.06

postcentral gyrus

-20.47, 23.90, 39.84

superior frontal

-33.22, 1.29, 5.70

insula

-50.74, -0.23, -9.71

superior temporal

-58.22, -10.57, -18.96

middle temporal

-53.69, -26.93, -21.94

inferior temporal

-54.28, -34.79, 31.34

supramarginal

-35.83, -42.63, 50.00

superior parietal

-42.60, -50.87, 22.47

inferior parietal

-53.93, -43.88, 0.51
-47.48, -19.26 , 6.55

banks
of
superior
temporal sulcus
transverse temporal

-42.24, -77.29, 4.81

lateral occipital

-10.45, 47.28, 13.50

superior frontal

-5.41, -10.39, 35.99

posterior cingulate

-8.41, -31.26, 27.05

isthmus cingulate

-6.69, -57.13, 17.09

precuneus
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-12.61, -77.93, 14.91

pericalcarine

-4.18, -75.36, 23.06

cuneus

-12.73, -23.40, 45.41

paracentral

-7.84, 40.16, -0.64

rostral anterior cingulate

-28.52, -5.33, -28.31

entorhinal

-27.18, -49.98, -11.27

fusiform

-25.83, -48.36, -2.05

lingual

-26.83, -40.03, -6.55

parahippocampal

-7.47, 16.15, -15.29

medial orbitofrontal

-9.10, 21.47, 25.17

caudal anterior cingulate

Table VI: Talairach coordinates and regions which are significantly different
between control and ALS-FTD groups in both cortical thickness and in cortical
volume (right side)

Talairach

Cortical

coordinates

regions

(vertex of cortical region) (X, significantly affected in ALS
Y, Z)

dementia
-50.36, 15.76, 16.36

pars opercularis

-37.55, 42.61,4.82

rostral middle frontal

-34.99, 9.32, 31.24

caudal middle frontal

-50.57, 3.39, 27.25

precentral gyrus

-54.28, -34.79, 31.34

supramarginal

-59.25, -15.11, 17.06

postcentral gyrus

-35.83, -42.63, 50.00

superior parietal
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-42.60, -50.87, 22.47

inferior parietal

-42.24, -77.29, 4.81

lateral occipital

-58.22, -10.57, -18.96

middle temporal

-53.93, -43.88, 0.51

banks superior
temporal sulcus

-50.74, -0.23, -9.71

superior temporal

-33.22, 1.29, 5.70

insula

-32.81, 21.55, -17.09

lateral orbitofrontal

-40.43, 38.91, -12.20

pars orbitalis

-20.47, 23.90, 39.84

superior frontal

-7.47, 16.15, -15.29

medial orbitofrontal

-7.84, 40.16, -0.64

rostral anterior
cingulate

-9.10, 21.47, 25.17

caudal anterior
cingulate

4.2.6

-12.73, -23.40, 45.41

paracentral

-5.41, -10.39, 35.99

posterior cingulate

-8.41, -31.26, 27.05

isthmus cingulate

-6.69, -57.13, 17.09

precuneus

-25.83, -48.36, -2.05

lingual

-28.52, -5.33, -28.31

entorhinal

Discussion

We have found that cortical thickness and cortical volume are reduced not only in
motor regions but also in non-motor frontal and temporal areas of ALS-FTD patients
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compared to control subjects, as described above. Frontal and temporal lobes are mainly
responsible for cognitive functions, including memory, object identification, facial
recognition. Absence of significant differences between control subjects and other (nondemented) ALS patients suggests a subcortical axonal and not primarily perikaryal
neurodegenerative process in the latter patients. Therefore, the significant reductions in
cortical volume and thickness we identified in ALS-FTD patients support our hypothesis
that primary neurodegeneration in these patients occurs in the perikaryon, as a
neuronopathy. Little has been studied regarding cortical thickness in ALS patients. To our
knowledge, only one study by Roccatagliata and colleagues (also using Freesurfer)18
compared cortical thickness in 14 ALS patients and 12 control subjects over 3 regions of
interest: precentral, postcentral and lateral occipital cortices. Cortical thickness was
significantly reduced only in the precentral region and no correlations were observed
between cortical thickness and clinical scores. Our study, on the other hand, found
significant reductions in cortical thickness in precentral, postcentral (included both gyri
and sulci) and lateral occipital cortices only in ALS-FTD patients, but not in ALS patients
without dementia (i.e., in the other subgroups). It is difficult to determine the reason for
the discrepant results between the two studies because we classified our patients based on
the presence of prominent UMN signs, CST hyperintensities, or FTD, whereas the ALS
patients of Roccatagliata et al examined ALS patients with a combination of UMN and
LMN signs and either bulbar or spinal onset but no dementia18 Nonethess, discrepancies
in results of published VBM ALS studies arises when patients with differing clinical
signs are included in the same group5,7,14, as was the case in the study by Roccatagliata
and colleagues18. Significant cortical thinning only in ALS-FTD patients and not in any

101

of the other ALS subgroups further emphasizes the need to categorize ALS patients based
on their clinical phenotype. This will likely lead us to a better understanding of different
pathophysiological mechanisms involved in ALS.
Use of cortical thickness analysis to identify significant decreases in cortical
thickness

and

volume

in

ALS-FTD

patients

demonstrates

the

additional

perspective/dimension obtained compared to VBM analysis. Cortical thickness analysis
revealed that volume reduction (also seen by VBM) is due to decreased thickness and not
by changes in cortical surface area. However, cortical surface area reductions have been
observed in normal aging29 and in Alzheimer’s disease15. However, visual comparison of
figures 30 and 31 shows more cortical regions showing thinning (30) than atrophy (31).
Although the reason for this is unclear, one possibility is that cortical thinning may be a
more sensitive change than obvious volume decrease (atrophy); since cortical area is
unchanged, it may be masking cortical volume changes (since volume =thickness*area).

4.2.7

Conclusion

Our results clearly demonstrate that the decreased cortical volume (by VBM) is due
to reduced cortical thickness and that this occurs in patients with ALS-FTD. This
suggests primary pathology occurring at the cortical neuron cell body (perikaryon) as a
neuronopathy in this ALS subgroup. Such cortical thinning occurs only in ALS-FTD
patients but not in the other ALS patient subgroups in which neurodegeneration may be
primarily subcortical, affecting axons as a “dying back” process. Our findings suggest
differences in the underlying neurodegenerative processes in these subgroups of ALS
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patients, and support the need for subclassification of patients based on clinical
phenotype in further ALS research.

4.2.8

Limitations and Future scope

The major limitations of this study were the small control group size and the need
for manual intervention to edit out non-brain regions not removed during the automated
brain extraction step, and possibly introducing some operator bias. The latter possibility
can be assessed by measuring intra-operator reliability in the future.
Results obtained from cortical thickness analysis can be combined with DTI metrics to
evaluate the contribution of cortical degeneration (neuronopathy) and subcortical
degeneration (axonopathy) in each of the ALS patient subgroups. A correlation map can
be obtained between reductions of cortical thickness and cortical volume to better
understand the relative interaction of these two measures. It would be worthwhile
examining other cortical measures such as average convexity (which measures the
depth/height of each point above an average surface), smoothed mean curvature and
Jacobian matrix (amount of anatomical variability between subjects). These parameters
may provide more information about the forms and complexity of cortical degeneration
in ALS.
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CHAPTER V
CONCLUSION

The etiology and site of origin of ALS are unknown. Neurodegeneration can
begin either in the upper motor neuron (UMN) or lower motor neuron (LMN), and even
within an UMN origin, neurodegeneration can be an axonopathy or a neuronopathy.
Based on preliminary data we hypothesize that ALS is predominantly an axonopathy, but,
in ALS patients with frontotemporal dementia (FTD), it is neuronopathy. We also
hypothesize that onset of neurodegeneration in patients with typical ALS is more caudal
along the corticospinal tract (CST) when compared with UMN-predominant ALS.Axonal
integrity will be investigated using T2 relaxometry and DTI, while neuronal integrity will
be assessed by quantitative methods of voxel-based morphometry (VBM) and cortical
thickness on qualitative T1-weighted images.
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Study 1
Many clinical studies employ dual echo fast spin echo (FSE) sequence for
measuring T2 relaxation times, although this is prone to high spatial frequency effects
depending on the brain region of interest. Therefore in this study we evaluated the
accuracy of T2 relaxation time measurements from dual echo FSE sequence relative to
more robust multiple echo spin echo (SE) sequence prior to employing the former to
evaluate pathologic changes in ALS. The results showed large systematic errors when
using dual echo FSE sequence relative to multiple echo SE sequence. Therefore, we
conclude that future T2 relaxometry studies employ multi-echo SE sequence or CPMG
sequence for accurate and reliable results.

Study 2
Axonal integrity in ALS patients was evaluated using scalar DTI metrics. We also
explored the usefulness of radial and axial diffusivities, Westin’s linear and planar indices
which are yet to be studied in ALS. We believed that axial and radial diffusivities,
Westin’s

linear

and

planar

indices

provide

additional

information

about

pathophysiological changes in ALS when compared to the commonly used metrics of FA
and MD.
1) All diffusion tensor metrics from DTI showed significant differences between ALS
patients compared to control sunjects. Notably, subgroup of classic ALS patients
showed abnormalities at more caudal levels of CST, supporting our hypothesis that
site of maximal neurodegeneration (and possibly origin) in these patients is more
caudal than in the UMN-predominant ALS subgroup.
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2) Absence of significant differences in any DTI metrics of CST hyperintense and CST
non hyperintense ALS groups, supporting our hypothesis that divergent pathologies
occur in the subcortical axons (e.g. spinal cord).
3) Axial and radial diffusivities provided novel information about pathophysiology of
ALS in that they showed not only significant differences between ALS subgroups but
also showed significant difference at more rostral levels of CST which were not
observed with FA metrics. Westin’s linear and planar indices identified fiber crossings
which were otherwise not distinguished with FA.
In general DTI metrics revealed group specific differences which clearly supported
our view that better insight into the pathophysiological mechanisms of ALS will be
obtained by categorizing ALS patients into subgroups based on clinical phenotypes.
Study 3
Neuronal integrity in grey matter structures was evaluated by measuring changes
in grey matter volume, using voxel-based morphometry (VBM) method, and cortical
thickness in ALS patients and control subjects. Since volume change could result from
changes in cortical thickness, cortical surface area, or both, cortical thickness
measurements were employed to investigate this. Both VBM and cortical thickness
results showed significant reduction in grey matter volume (by VBM) and thinning of
cerebral cortex occurred only in ALS dementia group when compared to controls. This
supported our hypothesis of early perikaryal degeneration (neuronopathy) in this ALS
subgroup and resultant global anterograde wallerian degeneration. Absence of significant
reductions in cortical volume and thickness in other ALS patient subgroups supports our
hypothesis that neuronal degeneration in these patients is primarily an axonopathy. Lack
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of cortical surface area reductions clearly demonstrates that volume changes found by
VBM are due to decreased cortical thickness and not cortical surface area. This provides
additional insight into pathological changes in ALS brain.
To our knowledge, this is the first clinical study in ALS with a sufficiently large
sample size that allows subcategorizing of ALS patients by clinical features to reveal
subgroup specific differences in brain pathology using DTI metrics, VBM and cortical
thickness measures. These findings suggest that ALS pathogenesis is variable among
patients and support the notion that ALS is not a single disease but rather a syndrome.
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APPENDIX

Histograms of T2 relaxation error values along CST and in whole brain grey
matter (GM) and white matter (WM) structures in all 8 subjects under study (Chapter 2)
Subject 1
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CST Right
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